Claims for Patent: 10,112,972

Summary for Patent: 10,112,972

Title:	Process for production of fibrinogen and fibrinogen produced thereby
Abstract:	A process for purifying fibrinogen from a fibrinogen containing source by precipitation of fibrinogen by a precipitating agent from a fibrinogen containing solution in the presence of one or more chelating agent(s) and removal of the supernatant from the fibrinogen paste, characterized in that fibrinogen is extracted from the paste forming a liquid fraction containing fibrinogen, and an undissolved residue, which is separated from the liquid.
Inventor(s):	Schulz; Petra (Vienna, AT), Gehringer; Werner (Vienna, AT), Schon; Friedrich (Vienna, AT), Leitinger; Caroline (Vienna, AT), Romisch; Jurgen (Vienna, AT), Pape; Rainer (Vienna, AT)
Assignee:	OCTAPHARMA AG (Lachen, CH)
Application Number:	14/382,712
Patent Claims:	1. A process for purifying fibrinogen from a fibrinogen containing source, the process comprising precipitating fibrinogen with a precipitating agent from the fibrinogen containing source in the presence of one or more chelating agent(s) to form a fibrinogen paste, removing the supernatant from the fibrinogen paste, extracting fibrinogen from the fibrinogen paste in an aqueous medium void of the chelating agent(s) for a suitable extraction time thereby forming a liquid fraction containing fibrinogen and an undissolved residue, and separating the undissolved residue from the liquid fraction containing fibrinogen, wherein addition of one or more protease inhibitor(s) is omitted in all steps of the process, the fibrinogen is precipitated in a temperature range of from 4.1.degree. C. to 40.degree. C., and the one or more protease inhibitor(s) is selected from the group consisting of C1-protease inhibitors, trypsin inhibitors, thrombin inhibitors, antithrombin-III (AT-III), heparin-cofactor-II, aprotinin, pepstatin, leupeptin and epsilon-aminocaproic acid. 2. The process of claim 1, wherein the one or more chelating agent(s) is a Ca.sup.2+-chelating agent selected from the group consisting of 1,2-bis(o-amino)ethane-N,N,N',N'-tetraacetic acid (BAPTA), diethylene-triamine-pentaacetic acid (DTPA), ethylenediamine-tetraacetic acid (EDTA), ethylene-glycol-tetraacetic acid (EGTA) and nitrilo-triacetic acid (NTA). 3. The process of claim 1, wherein the concentration of the chelating agent is in a range of 3 mM to 100 mM. 4. The process of claim 1, wherein the concentration of the chelating agent is in a range of 5 mM to 50 mM. 5. The process of claim 1, wherein the concentration of the chelating agent is in a range of 5 mM to 20 mM. 6. The process of claim 1, wherein the fibrinogen paste is extracted in a buffer for 10 to 120 minutes to obtain the liquid fraction containing fibrinogen. 7. The process of claim 6, wherein the buffer is TRIS buffer. 8. The process of claim 6, wherein the obtained liquid fraction containing fibrinogen is filtered to yield a filtrate and the filtrate is contacted with an anion exchange resin comprising trimethyl-amino groups grafted to a hydroxylated methacrylic polymer backbone via linking groups and loosely bound substances are washed from the resin. 9. The process of claim 8, wherein fibrinogen is desorbed from the anion exchange resin with an elution buffer containing sodium citrate, sodium chloride, and glycine. 10. The process of claim 9, wherein the desorbed fibrinogen solution is nanofiltered to obtain a nanofiltered fraction. 11. The process of claim 10, wherein the nanofiltered fraction is concentrated, formulated, sterile filtered and/or filled into suitable final containers. 12. The process of claim 11, wherein the final containers are selected from glass vials or bottles or plastic bags comprising a membrane. 13. The process of claim 11, wherein the nanofiltered fraction is lyophilised in the final container. 14. The process of claim 10, wherein the elution buffer contains about 1.5 g/l sodium citrate, about 7.0 g/l sodium chloride and about 10.0 g/l glycine. 15. The process of claim 10, wherein the elution buffer is adjusted to a pH of about 7.0 and a conductivity of 13.1-15 mS/cm. 16. The process of claim 9, wherein the loosely bound substances are washed with a wash buffer of about 12.0 mS/cm conductivity. 17. The process of claim 7, wherein the fibrinogen paste is extracted in about 20 mM TRIS buffer or a pH of about 8.0. 18. The process of claim 1 comprising the steps of a) solubilizing cryoprecipitate at about neutral pH, b) subjecting the solubilised cryoprecipitate of step a) to adsorption with Al(OH).sub.3 and removing the resulting gel, c) virus inactivating the resulting solution of step b) by a solvent/detergent (S/D) treatment, extracting the S/D reagents with vegetable oil and contacting the water-phase with a tri-methyl-amino ethyl (TMAE) resin at a pH-value of 6.9-7.1 and an osmolality of 570-610 mosmol/l, d) adding at least one chelating agent to the resulting water phase of step c), e) precipitating fibrinogen from the chelating agent containing water phase from step d), by adding glycine until a final concentration of about 1M glycine is reached, and separating of the resulting fibrinogen paste, f) extracting fibrinogen from the fibrinogen paste by a 20 mM TRIS buffer at a pH of about 8.0, filtering the liquid fraction containing fibrinogen, g) loading the filtered solution of step f) onto an anion exchange resin comprising trimethyl-amino groups grafted to a hydroxylated methacrylic polymer backbone via linking groups and washing off loosely bound substances with a wash buffer of about 12.0 mS/cm conductivity, h) eluting fibrinogen from the anion exchange resin with an elution buffer containing about 1.5 g/l sodium citrate, about 7.0 g/l sodium chloride and about 10.0 g/l glycine, adjusted to a pH of about 7.0 and a conductivity of 13.1-15 mS/cm, i) filtering the eluted fibrinogen of step h) over at least one nanofilter, and j) concentrating, formulating, sterile filtering, filling the nanofiltered fibrinogen into suitable containers, and optionally lyophilizing the nanofiltered fibrinogen. 19. The process of claim 18 wherein the concentration of the chelating agent in the water phase is 3 mM to 100 mM. 20. The process of claim 1, wherein the precipitating agent is selected from the group consisting of amino acids, polyethylene glycol, a salt in high concentrations, and combinations thereof, wherein the salt contains monovalent metal ions. 21. The process of claim 20, wherein the salt is an alkali metal or ammonium. 22. The process of claim 20, wherein the precipitating agent is an amino acid. 23. The process of claim 22, wherein the amino acid is glycine. 24. The process of claim 23, wherein the glycine is at a concentration of about 1M. 25. The process of claim 1, wherein the temperature range is from 5.degree. C. to 37.degree. C.

Details for Patent 10,112,972

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Bayer Healthcare Pharmaceuticals Inc.	TRASYLOL	aprotinin	Injection	020304	December 29, 1993	10,112,972	2033-03-12
Csl Behring Gmbh	RIASTAP	fibrinogen concentrate (human)	For Injection	125317	January 16, 2009	10,112,972	2033-03-12

International Patent Family for US Patent 10,112,972

Country	Patent Number	Estimated Expiration
World Intellectual Property Organization (WIPO)	2013135684
United States of America	2019016755
United States of America	2015045539
United States of America	11401300
Russian Federation	2663792
Russian Federation	2014139974
Mexico	351340